COVID-19: Vaccines and Therapeutics
The Moderna COVID-19 vaccine continued to protect 33 healthy adults six months after receiving the second dose, according to an ongoing clinical trial examining the vaccine’s durability, published in the New England Journal of Medicine.
The AHA unveiled several new resources to aid hospitals’ and health systems’ efforts to increase the public’s confidence in COVID-19 vaccines.
All U.S. adults will become eligible for the COVID-19 vaccine by April 19, President Biden announced. That’s a couple weeks sooner than the May 1 target he announced last month.
A roundup of new resources for increasing the public’s confidence in COVID-19 vaccines.
Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced.
The Food and Drug Administration said that Moderna can add up to 50% more doses per vial of its COVID-19 vaccine. Moderna had been shipping 10-dose vials; the FDA’s change will enable shipments to contain up to 15 doses per vial.
The Department of Health and Human Services launched a nationwide network of trusted voices to encourage vaccinations and increase vaccine confidence.
The Pfizer-BioNTech COVID-19 vaccine was well tolerated and demonstrated 100% efficacy and robust antibody responses in a phase 3 clinical trial in 2,260 children aged 12-15, the vaccine’s makers announced.
As part of AHA’s Joining Hands for Greater Impact series, we talk to Atrium Health, American Airlines and Charlotte Douglas International Airport representatives about how they came together to “get shots in arms” in Charlotte, N.C.
BREAKING NEWS related to vaccine effectiveness in children and the novel coronavirus pandemic that we wanted to share.